Challenge 21- InMutaGene Phase 2 awarded!

GeneWerk leads winning team

Individualized Genotoxicity (InGeTox) Assay – A Cross-Functional Team Initiative

Challenge 21- InMutaGene Phase 2 awarded!

This Challenge aims to develop a human relevant risk assessment system that will improve the safety of novel gene therapy products and reduce the reliance on animal models. The winning team is led by GeneWerk and includes Brunel University London, University College London, King’s College London and The Natural and Medical Sciences Institute, at the University of Tübingen, with GlaxoSmithKline and Novartis acting as Sponsors.

They have already set up the basis of a standardised assay for IndividualisedGenotoxicity testing (InGeTox) to assess vector safety and efficacy using human induced pluripotent stem cells. Vector-related factors that cause genotoxicity will be measured, including effects on cancer gene expression by vector promoters and enhancers, aberrant transcript forms or gene splicing, host epigenetic responses to gene transfer and therapeutic gene expression.


Further information

Go back